ArticleJournal of bone oncology2026
Metastatic renal cell carcinoma: risk of rapid progression to pathological fractures and factors influencing post-treatment survival - a Swedish Nationwide cohort study.
Article in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Renal Cell Carcinoma (RCC) represents about 2% of all cancers in Sweden. While RCC is known for its potential to metastasize to the skeleton, few studies have examined the risk factors for pathological fractures and their impact on survival. The Fuhrman grade and AJCC staging systems are commonly used to assess disease aggressiveness, but their relationship to fracture risk and post-fracture outcomes remains unclear. Methods: This study cross-linked data from the Swedish Fracture Register (SFR) and the Swedish Renal Cancer Register (SNR) to identify RCC patients with pathological fractures. Fracture characteristics, cancer staging (Fuhrman, TNM, AJCC), and histological subtypes were analysed. Survival was estimated using the Kaplan-Meier method. Results: One hundred four RCC patients (72 men, 32 women) with pathological fractures were included, with clear cell carcinoma being most common (n = 93). Fuhrman grade 3 (n = 34) and fractures in the femur (n = 44) and humerus (n = 37) predominated. Median time from cancer diagnosis to fracture was 11 months. Higher Fuhrman grade, TNM, and AJCC stages were significantly associated with shorter time to fracture (p < 0.001). The median overall survival was 31 months and was related to Fuhrman grade (p = 0.013) and AJCC stage (p < 0.001). The median survival post-fracture was 8 months, with no significant association with cancer grade or stage. Conclusion: Advanced Fuhrman grade and AJCC stage predict faster progression to pathological fractures in RCC. Given the poor prognosis after pathological fractures, early risk stratification and individualized treatment approaches are essential to improve outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.